subscribeSubscribe
Kymera doubles down on protein degraders for immunology

Kymera doubles down on protein degraders for immunology
ENDPTS
04 Jan 2024
Share Share
Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113

Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113
ACCESSWIRE
27 Nov 2023
Share Share
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy
BUSINESSWIRE
11 Oct 2023
Share Share
BMS’s Sotyktu recommended for NHS use for adult patients with psoriasis

BMS’s Sotyktu recommended for NHS use for adult patients with psoriasis
PHARMAFILE
28 Jun 2023
Share Share
BMS says TYK2 inhibitor Sotyktu gains EU approval in psoriasis

BMS says TYK2 inhibitor Sotyktu gains EU approval in psoriasis
PRESS RELEASE
29 Mar 2023
Share Share
BMS debuts first psoriasis drug ad on Grammys, leading chorus of pharma brands

BMS debuts first psoriasis drug ad on Grammys, leading chorus of pharma brands
Beth Snyder Bulik ENDPTS
06 Feb 2023
Share Share
BMS holds on to high Sotyktu hopes, plays down Otelza threat

BMS holds on to high Sotyktu hopes, plays down Otelza threat
Zoey Becker FIERCE PHARMA
02 Feb 2023
Share Share
BMS Announces Positive CHMP Opinion for Once-Daily Sotyktu for Plaque Psoriasis

BMS Announces Positive CHMP Opinion for Once-Daily Sotyktu for Plaque Psoriasis
BUSINESSWIRE
27 Jan 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share
Nimbus posts psoriasis data on rival to Bristol Myers` Sotyktu

Nimbus posts psoriasis data on rival to Bristol Myers` Sotyktu
Nick Paul Taylor FIERCEBIOTECH
30 Nov 2022
Share Share